摘要:
Amino acids (136 to 142) and amino acids (162 to 168) of human osteopontin constitute two sites at which osteopontin interacts with α4 integrins. Products capable of disrupting those interactions are useful in therapy, particularly in the treatment of inflammatory diseases.
摘要:
Amino acids 136 to 142 and amino acids 162 to 168 of human osteopontin constitute two sites at which osteopontin interacts with α4 integrins. Products capable of disrupting those interactions are useful in therapy, particularly in the treatment of inflammatory diseases.
摘要:
A method for the identification of a modulator of the interaction between latency asssociated peptide (LAP) of transforming growth factor β1 (TGF-β1) and the integrin avb3, which method comprises: (a) providing, as a first component, LAP-β1 or a functional variant thereof (b) providing, as a second component, integrin avb3 or a functional variant thereof (c) contacting the two components with a test product under conditions that, in the absence of the test product, would permit the two components to interact; and (d) determining whether the test product is capable of modulating the interaction between the first and second components, thereby to determine whether the test product is a modulator of the interaction between LAP-β1 and integrin avb3.
摘要翻译:鉴定转化生长因子β1(TGF-β1)的潜伏相关肽(LAP)与整联蛋白α3β3之间相互作用的调节剂的方法, 该方法包括:(a)作为第一组分提供LAP-β1或其功能变体(b)提供作为第二组分的整联蛋白α3/ >或其功能变体(c)在不存在测试产物的情况下允许两种组分相互作用的条件下将两种组分与测试产物接触; 和(d)确定测试产品是否能够调节第一和第二组分之间的相互作用,从而确定测试产品是否是LAP-β1和整联蛋白之间相互作用的调节剂, b 3 3。
摘要:
The present disclosure provides an isolated protein comprising at least one antibody variable region that is capable of binding to peptidase inhibitor 16 (PI16), wherein the protein is also capable of competitively inhibiting binding of an antibody produced by a hybridoma designated CRCBT-02-001 deposited with the ATCC under Accession Number PTA-10685 to PI16. The present invention also provides use of the protein, e.g., in diagnosis, therapy or to isolate cells, preferably Treg cells.
摘要:
Amino acids 136 to 142 and amino acids 162 to 168 of human osteopontin constitute two sites at which osteopontin interacts with α4 integrins. Products capable of disrupting those interactions are useful in therapy, particularly in the treatment of inflammatory diseases.
摘要:
Targeted binding agents, such antibodies directed to the antigen αVβ6 and uses of such agents are described. In particular, fully human monoclonal antibodies directed to the antigen αVβ6 are disclosed. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3 are disclosed. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies are also disclosed.
摘要:
A method for the identification of a modular of the interaction between latency associated peptide (LAP) of transforming growth factor β3 (TGF-β3) and αv integrin, which method comprises: (a) providing, as a first component, LAP-β3 or a functional variant thereof; (b) providing, as a second component, and αv integrin or a functional variant thereof; (c) contacting the two components with a test product under conditions that, in the absence of the test product, would permit the two components to interact; and (d) determining whether the test product is capable of modulating the interaction between the first and second components, thereby to determine whether the test product is a modulator of the interaction between LAP-β3 and the integrin.
摘要:
The present disclosure provides an isolated protein comprising at least one antibody variable region that is capable of binding to peptidase inhibitor 16 (PI16), wherein the protein is also capable of competitively inhibiting binding of an antibody produced by a hybridoma designated CRCBT-02-001 deposited with the ATCC under Accession Number PTA-10685 to PI16. The present invention also provides use of the protein, e.g., in diagnosis, therapy or to isolate cells, preferably Treg cells.
摘要:
The present invention provides markers of regulatory T (Treg) cells, preferably, cell surface markers of Treg cells and uses of those markers or compounds that bind thereto to identify or isolate Treg cells or to diagnose/prognose/treat/prevent Treg-mediated conditions. The present invention also provides methods for identification and/or isolation of Treg cell subpopulations and such isolated subpopulations of Treg cells.